Transfer of DNA tests from research to routine laboratories: some lessons from the French experience in the case of Duchenne muscular dystrophy.
In the last few years, the activity of research laboratories has led to the emergence of new DNA diagnostic tests in France. They permit the origin of genetic diseases to be identified and provide an answer concerning the detection of carriers and prevention. Nevertheless, given this, new actors have emerged on the health care scene: the research workers who developed the tests and who work in public research laboratories. The economic question of the transfer of the test practice from research to hospital laboratories is the main topic of this paper, taking Duchenne Muscular Dystrophy (DMD) DNA diagnostic tests as the example. After a presentation of the complexity of DNA tests for DMD, the fact that financial and human constraints do not allow the actors to continue to produce the DNA tests is discussed. The financial role of the non-profit-making associations is then explained and leads to the conclusion that a more global policy on DNA tests, such as carried out in the UK and the Netherlands, should be adopted in France by the Social Security if it wants DNA testing activity to be pursued.
Hirtzlin
I
I
Hôpital de Bicêtre, France.
D019411:Clinical Laboratory Techniques / Q000191:economics*; D005380:Financing, Government; D005602:France; D005820:Genetic Testing / Q000191:economics*; D006788:Hospitals, Voluntary; D006801:Humans; D007755:Laboratories, Hospital / Q000639:trends*; D009136:Muscular Dystrophies / Q000175:diagnosis* / Q000235:genetics; D009313:National Health Programs; D011050:Policy Making; D012106:Research; D018581:Technology Transfer